Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Strati P, Ahmed MAA, Fowler N, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS.

Haematologica. 2019 Oct 10. pii: haematol.2019.230649. doi: 10.3324/haematol.2019.230649. [Epub ahead of print]

2.

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y.

Leuk Lymphoma. 2019 Sep 18:1-9. doi: 10.1080/10428194.2019.1663418. [Epub ahead of print]

PMID:
31533521
3.

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS.

Leuk Lymphoma. 2019 Jun 24:1-8. doi: 10.1080/10428194.2019.1627535. [Epub ahead of print]

PMID:
31234671
4.

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS.

Blood. 2019 Jun 27;133(26):2800-2802. doi: 10.1182/blood.2019000888. Epub 2019 May 17. No abstract available.

PMID:
31101626
5.

[Low-risk community-acquired pneumonia: implications of its outcome due to the determining factors for admission not contemplated by the scores].

Samaniego FA, Ghelfi AM, Rodríguez MS.

Semergen. 2019 May 14. pii: S1138-3593(19)30097-8. doi: 10.1016/j.semerg.2019.02.011. [Epub ahead of print] Spanish.

PMID:
31101491
6.

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS.

Blood Adv. 2019 May 14;3(9):1356-1367. doi: 10.1182/bloodadvances.2018029140.

7.

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B.

Head Neck. 2019 May;41(5):1546. doi: 10.1002/hed.25738. Epub 2019 Mar 19. No abstract available.

PMID:
30990235
8.

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.

Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2432-2440. doi: 10.1080/10428194.2019.1597081. Epub 2019 Apr 3.

PMID:
30942648
9.

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes.

Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):381-389. doi: 10.1016/j.clml.2019.02.011. Epub 2019 Feb 26.

PMID:
30935940
10.

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.

Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH.

Br J Haematol. 2019 Jun;185(5):874-882. doi: 10.1111/bjh.15843. Epub 2019 Mar 28.

11.

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F.

Br J Haematol. 2019 May;185(4):670-678. doi: 10.1111/bjh.15814. Epub 2019 Feb 28.

PMID:
30820940
12.

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.

Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS.

Am J Hematol. 2019 Jun;94(6):E150-E153. doi: 10.1002/ajh.25447. Epub 2019 Mar 6. No abstract available.

PMID:
30785215
13.

Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.

Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP.

Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2.

PMID:
30410039
14.

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.

Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Aug 17. doi: 10.1097/IOP.0000000000001215. [Epub ahead of print]

PMID:
30124609
15.

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B.

Head Neck. 2018 Jun;40(6):1335. doi: 10.1002/hed.25149. Epub 2018 Feb 21. No abstract available.

PMID:
29851218
16.

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML.

Br J Haematol. 2018 Aug;182(3):404-411. doi: 10.1111/bjh.15411. Epub 2018 May 22.

PMID:
29785709
17.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.

Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.

18.

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA.

Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5. No abstract available.

19.

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y.

PLoS One. 2018 Mar 14;13(3):e0191461. doi: 10.1371/journal.pone.0191461. eCollection 2018.

20.

Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.

Hosry J, Miranda RN, Samaniego F, Economides MP, Torres HA.

Int J Cancer. 2018 Mar 1;142(5):940-948. doi: 10.1002/ijc.31110. Epub 2017 Nov 3.

21.

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y.

Leuk Lymphoma. 2018 Apr;59(4):863-870. doi: 10.1080/10428194.2017.1359741. Epub 2017 Aug 9.

PMID:
28792260
22.

Targeting nucleolin for better survival in diffuse large B-cell lymphoma.

Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Courty J, Young KH, Sehgal L, Samaniego F.

Leukemia. 2018 Mar;32(3):663-674. doi: 10.1038/leu.2017.215. Epub 2017 Jul 10.

23.

The oncologic burden of hepatitis C virus infection: A clinical perspective.

Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V.

CA Cancer J Clin. 2017 Sep;67(5):411-431. doi: 10.3322/caac.21403. Epub 2017 Jul 6. Review.

24.

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A.

Blood. 2017 Jul 27;130(4):472-477. doi: 10.1182/blood-2017-02-766121. Epub 2017 May 18.

25.

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.

Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M.

Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13.

26.

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B.

Head Neck. 2017 Jun;39(6):1095-1100. doi: 10.1002/hed.24717. Epub 2017 Apr 3. Erratum in: Head Neck. 2018 Jun;40(6):1335. Head Neck. 2019 May;41(5):1546.

27.

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH.

Br J Haematol. 2017 Apr;177(2):263-270. doi: 10.1111/bjh.14541. Epub 2017 Mar 24.

28.

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.

Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F.

J Transl Med. 2016 Dec 20;14(1):346. doi: 10.1186/s12967-016-1100-9.

29.

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y.

Br J Haematol. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16.

30.

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.

Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA.

Lancet Oncol. 2017 Jan;18(1):100-111. doi: 10.1016/S1470-2045(16)30626-X. Epub 2016 Dec 3.

31.

Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F.

Haematologica. 2017 Feb;102(2):373-380. doi: 10.3324/haematol.2016.144964. Epub 2016 Oct 14.

32.

Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.

Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct;33(5):355-360. doi: 10.1097/IOP.0000000000000789.

PMID:
27636243
33.

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A.

Br J Haematol. 2016 Oct;175(2):290-299. doi: 10.1111/bjh.14237. Epub 2016 Jul 22.

PMID:
27448187
34.

Resolution of lung adenocarcinoma after discontinuation of ibrutinib.

Khashab T, Loghavi S, Konoplev SN, Samaniego F.

BMJ Case Rep. 2016 Jul 18;2016. pii: bcr2016215342. doi: 10.1136/bcr-2016-215342.

35.

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ.

Cancer. 2016 Oct 15;122(20):3145-3151. doi: 10.1002/cncr.30173. Epub 2016 Jun 28.

36.

Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy.

Economides MP, Mahale P, Turturro F, Hosry J, Samaniego F, Granwehr BP, Torres HA.

Leuk Lymphoma. 2017 Feb;58(2):485-488. Epub 2016 Jun 27. No abstract available.

PMID:
27348218
37.

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA.

JAMA Oncol. 2016 Aug 1;2(8):1065-9. doi: 10.1001/jamaoncol.2016.1396.

PMID:
27227654
38.

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA.

Ann Oncol. 2016 Jul;27(7):1317-23. doi: 10.1093/annonc/mdw169. Epub 2016 Apr 18.

39.

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH.

Ann Oncol. 2016 May;27(5):895-901. doi: 10.1093/annonc/mdw026. Epub 2016 Jan 22.

PMID:
26802151
40.

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE.

Br J Haematol. 2016 Jan;172(1):80-8. doi: 10.1111/bjh.13796. Epub 2015 Dec 9.

41.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L.

Lancet Oncol. 2016 Jan;17(1):48-56. doi: 10.1016/S1470-2045(15)00438-6. Epub 2015 Nov 28.

PMID:
26640039
42.

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.

Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA.

Br J Haematol. 2015 Dec;171(5):726-35. doi: 10.1111/bjh.13659. Epub 2015 Sep 11.

43.

Small Lymphocytic Lymphoma Presenting with Hypopituitarism.

Moore JA, Moore MB, Samaniego F, Pinnix CC, Moore DF Jr.

Am J Med. 2016 Jan;129(1):e9-e10. doi: 10.1016/j.amjmed.2015.08.016. Epub 2015 Sep 5. No abstract available.

PMID:
26344628
44.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y.

Br J Haematol. 2015 Nov;171(4):509-16. doi: 10.1111/bjh.13628. Epub 2015 Aug 10.

PMID:
26260306
45.

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY.

Haematologica. 2015 Nov;100(11):e454-7. doi: 10.3324/haematol.2015.131144. Epub 2015 Aug 6. No abstract available.

46.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A.

Br J Haematol. 2015 Nov;171(4):463-70. doi: 10.1111/bjh.13603. Epub 2015 Jul 27.

47.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2901. doi: 10.1038/jid.2015.259. Epub 2015 Jul 16. No abstract available.

48.

Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma.

Khashab T, Sehgal L, Medeiros LJ, Samaniego F.

BMJ Case Rep. 2015 Jun 12;2015. pii: bcr2014209014. doi: 10.1136/bcr-2014-209014.

49.

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F.

J Hematol Oncol. 2015 Jun 6;8:63. doi: 10.1186/s13045-015-0161-1.

50.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2775-2784. doi: 10.1038/jid.2015.204. Epub 2015 Jun 3. Erratum in: J Invest Dermatol. 2015 Nov;135(11):2901.

Supplemental Content

Loading ...
Support Center